Michael (PhD theoretical chemistry and protein crystallography) is Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc, previously Exec Director of Windber Research Institute (Chan Soon-Shiong Institute for Molec Med) 2003-2007. He is Adj Professor of Pharmacology and Physiology, Drexel College of Medicine, Res Professor of Biology, University of Massachusetts-Lowell and Adj Professor of Drug Discovery, First Hospital, Wenzhou Medical University and Fudan University. He serves on the Advisory Board for the International Park for Translational Biomedicine (Shanghai) and the Center of Biomedi and Health Res in Data Sciences, Univ Mass(Lowell). Previously, he was Director, Computational Biology and Biomedical Informatics, Univ of Penn Cancer Center 2000-2003. He served as Global Head of Computational Genomics, Roche Pharma and Director, Bioinformatics and Pharmacogenomics, Wyeth Pharma, Director of Genomics for Vysis, Inc. He co-founded Prosanos, Inc (now United BioSource) (2000). He was Associ Professor of. Pharmacology and of Physiology/Biophysics at Mount Sinai School of Medicine. He advises on digital health and quantum computing and is on the Board of the Nathaniel Adamczyk Foundation in Pediatric ARDS. Michael chaired the Informatics Program and the Translational Medicine for the PhRMA Foundation and served on Scientific Advisory Board. He is on the Editorial Board for the Journal of Translational Medicine, for Clinical and Translational Medicine and for Molecular Medicine and Therapeutics, for Clinico-Economics and Outcomes Research, Exploratory Research and Hypothesis in Medicine and Biomedicine Hub. He is a member of the IUPAC Division on Human Health’s Medicinal Chemistry subcommittee. He served on the External Advisory Board for the INBRE (NIH) program for Delaware. He is an Invited Professor at the Shanghai Center for Bioinformatics Technology and of the Chinese Academy of Sciences and Project Leader for the Institute for Human Centered Health Innovation, co-lead of the EU IHI Learning CVD and CSO (United Cancer Center Network). He focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective. He utilizes systems-based, design thinking to represent and analyze risk/benefit in pharmaceutical development and healthcare and reimbursement. Current projects include: multiple sclerosis, heart failure, triple negative breast cancer, COVID and prematurity/infant-maternal morbidity and mortality.